Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial
Authors
Keywords
-
Journal
CIRCULATION
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-08-29
DOI
10.1161/circulationaha.121.056824
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
- (2021) David D. Berg et al. JAMA Cardiology
- Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction
- (2021) Muthiah Vaduganathan et al. JACC-Heart Failure
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of the Inflammatory‐Metabolic Phenotype of Heart Failure and a Preserved Ejection Fraction: a Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease
- (2020) Milton Packer et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF
- (2020) Alice M. Jackson et al. CIRCULATION
- Metabolomic profile in HFpEF vs HFrEF patients
- (2020) C. Hage et al. JOURNAL OF CARDIAC FAILURE
- Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
- (2020) Donato Cappetta et al. PHARMACOLOGICAL RESEARCH
- Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ‐ Heart Failure Association EURObservational Research Programme Heart Failure Long‐Term Registry
- (2020) Agnieszka Kapłon‐Cieślicka et al. ESC Heart Failure
- Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
- (2020) Kieran F. Docherty et al. CIRCULATION
- Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
- (2020) Milton Packer et al. CIRCULATION
- Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors
- (2020) Milton Packer JOURNAL OF CARDIAC FAILURE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiologic Characterization of Heart Failure with Reduced or Preserved Ejection Fraction Populations Identified Using Medicare Claims
- (2020) Rishi J. Desai et al. AMERICAN JOURNAL OF MEDICINE
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- (2019) Stefan D. Anker et al. EUROPEAN JOURNAL OF HEART FAILURE
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease
- (2019) C. David Mazer et al. CIRCULATION
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Causes and Temporal Patterns of 30‐Day Readmission Among Older Adults Hospitalized With Heart Failure With Preserved or Reduced Ejection Fraction
- (2018) Parag Goyal et al. Journal of the American Heart Association
- Obesity-Related Heart Failure With a Preserved Ejection Fraction
- (2018) Milton Packer et al. JACC-Heart Failure
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Mode of Death in Heart Failure With Preserved Ejection Fraction
- (2017) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Importance of Clinical Worsening of Heart Failure Treated in the Outpatient SettingCLINICAL PERSPECTIVE
- (2016) Naoki Okumura et al. CIRCULATION
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model
- (2016) Jennifer K. Rogers et al. STATISTICS IN MEDICINE
- Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
- (2014) S. Sha et al. DIABETES OBESITY & METABOLISM
- Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT
- (2014) Hicham Skali et al. EUROPEAN JOURNAL OF HEART FAILURE
- Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction
- (2014) Lars H. Lund et al. EUROPEAN JOURNAL OF HEART FAILURE
- Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST])
- (2010) Peter Carson et al. AMERICAN HEART JOURNAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started